Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GlycoMimetics Inc GLYC

Healthcare Biotechnology
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of... see more

Recent & Breaking News (NDAQ:GLYC)

GlycoMimetics to Present at Biocentury’s Newsmakers in the Biotech Industry Conference

Business Wire September 5, 2017

Stocks Under Scanner in the Biotech Space -- GlycoMimetics, Genocea Biosciences, Inotek Pharma, and Loxo Oncology

PR Newswire September 5, 2017

GlycoMimetics Reports Program Updates and Second Quarter 2017 Results

Business Wire August 3, 2017

GlycoMimetics to Receive European Patent for GMI-1271

Business Wire July 6, 2017

Technical Snapshots for These Biotech Stocks -- Merrimack Pharma, MannKind, GlycoMimetics, and Radius Health

PR Newswire June 28, 2017

GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors

Business Wire June 12, 2017

GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference

Business Wire June 5, 2017

GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting

Business Wire June 5, 2017

GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271

Business Wire May 31, 2017

GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire May 30, 2017

GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia

Business Wire May 25, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  May 24, 2017

GlycoMimetics Announces Pricing of Public Offering of Common Stock

Business Wire May 24, 2017

GlycoMimetics Announces Proposed Public Offering of Common Stock

Business Wire May 22, 2017

12 Biggest Mid-Day Losers For Monday

Benzinga.com  May 22, 2017

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  May 19, 2017

Mid-Afternoon Market Update: Dow Rises Over 100 Points; Perry Ellis Shares Gain After Strong Q1 Results

Benzinga.com  May 18, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  May 18, 2017

Stifel's ASCO Abstract Cheat Sheet

Benzinga.com  May 18, 2017

GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML

Business Wire May 18, 2017